公开(公告)号：US09546994B2

公开(公告)日：2017-01-17

申请号：US14421637

申请日：2013-08-13

申请人： Helmholtz Zentrum Munchen—Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH) ,  Deutsche Diabetes-Forschungsgesellschaft e.V.—Trager des Deutschen Diabetes-Zentrums Dusseldorf ,  Eberhard Karls Universitat Tubingen, Medizinische Fakultat

发明人： Wolfgang Rathmann ,  Christian Herder ,  Thomas Illig ,  Jerzy Adamski ,  Rui Wang-Sattler ,  Zhongao Yu ,  H.-Erich Wichmann ,  Hans-Ulrich Haring ,  Michael Roden ,  Annette Peters ,  Christine Meisinger ,  Martin Hrabe De Angelis ,  Thomas Meitinger

IPC分类号： G01N33/92 ,  G01N33/487 ,  G01N33/68 ,  G01N24/08 ,  G01N30/02 ,  G01N30/72 ,  G01N33/49

CPC分类号： G01N33/487 ,  G01N24/08 ,  G01N30/02 ,  G01N30/7206 ,  G01N33/49 ,  G01N33/6893 ,  G01N33/92 ,  G01N2030/025 ,  G01N2030/027 ,  G01N2500/10 ,  G01N2800/042 ,  G01N2800/50

摘要： The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric metabolite having the same molecular weight as acetylcarnitine C2 but different chemical formula; wherein a decrease in the amount of a metabolite selected from said first group or an increase in the amount of a metabolite selected from said second group as compared to the amount of the corresponding metabolite(s) of a control is indicative of a predisposition to develop type 2 diabetes mellitus. Further, the invention relates to a method of identifying a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith or serving as a lead compound for developing a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith and a method of selecting a therapy to prevent type 2 diabetes mellitus. Also, the invention relates to a kit.

摘要翻译： 本发明涉及鉴定受试者中2型糖尿病发病倾向的方法，所述方法包括以下步骤：在从所述受试者获得的样品中评估选自（a）的一种或多种代谢物的量， 第一组包括代谢物甘氨酸，溶血磷脂酰胆碱酰基C18：2，溶血磷脂酰胆碱酰基C17：0，溶血磷脂酰胆碱酰基C18：0，溶血磷脂酰胆碱酰基C18：1，磷脂酰胆碱酰基 - 烷基C34：2，磷脂酰胆碱酰基 - 烷基C36：2，磷脂酰胆碱酰基 - 烷基C36：3和具有与甘氨酸相同分子量的等压代谢物，溶血磷脂酰胆碱酰基C18：2，溶血磷脂酰胆碱酰基C17：0，溶血磷脂酰胆碱酰基C18：0，溶血磷脂酰胆碱酰基C18：1，磷脂酰胆碱酰基 - 烷基C34：2，磷脂酰胆碱酰基 - 烷基C36：2或磷脂酰胆碱酰基 - 烷基C36：3但化学式不同; 和/或（b）包含代谢物乙酰肉碱C2和具有与乙酰肉碱C2相同的分子量但不同化学式的等压代谢物的第二组; 其中与对照的相应代谢物的量相比，选自所述第一组的代谢物的量的减少或选自所述第二组的代谢物的量的增加表明发生倾向 2型糖尿病 此外，本发明涉及鉴定能够预防2型糖尿病和与其相关的疾病或作为用于开发能够预防2型糖尿病和相关疾病的化合物的铅化合物的化合物的方法，以及选择 治疗预防2型糖尿病。 此外，本发明涉及一种试剂盒。

公开(公告)号：US20150204839A1

公开(公告)日：2015-07-23

申请号：US14421637

申请日：2013-08-13

申请人： Helmholtz Zentrum Munchen-Deutsches Forschungszen- trum fur Gesundheit and Umweit (GmbH) ,  Deutsche Diabetes-Forschungsgesellschaft e.V.- Trager des Deutschen Diabetes-Zentrums Dusseldorf ,  Eberhard Karls Universitat Tubingen, Medizinische Fakultat

发明人： Wolfgang Rathmann ,  Christian Herder ,  Thomas Illig ,  Jerzy Adamski ,  Rui Wang-Sattler ,  Zhongao Yu ,  H.-Erich Wichmann ,  Hans-Ulrich Haring ,  Michael Roden ,  Annette Peters ,  Christine Meisinger ,  Martin Hrabe De Angelis ,  Thomas Meitinger

IPC分类号： G01N33/487 ,  G01N24/08 ,  G01N30/72 ,  G01N33/49 ,  G01N30/02

CPC分类号： G01N33/487 ,  G01N24/08 ,  G01N30/02 ,  G01N30/7206 ,  G01N33/49 ,  G01N33/6893 ,  G01N33/92 ,  G01N2030/025 ,  G01N2030/027 ,  G01N2500/10 ,  G01N2800/042 ,  G01N2800/50

摘要： The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric metabolite having the same molecular weight as acetylcarnitine C2 but different chemical formula; wherein a decrease in the amount of a metabolite selected from said first group or an increase in the amount of a metabolite selected from said second group as compared to the amount of the corresponding metabolite(s) of a control is indicative of a predisposition to develop type 2 diabetes mellitus. Further, the invention relates to a method of identifying a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith or serving as a lead compound for developing a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith and a method of selecting a therapy to prevent type 2 diabetes mellitus. Also, the invention relates to a kit.

摘要翻译： 本发明涉及鉴定受试者中2型糖尿病发病倾向的方法，所述方法包括以下步骤：在从所述受试者获得的样品中评估选自（a）的一种或多种代谢物的量， 第一组包括代谢物甘氨酸，溶血磷脂酰胆碱酰基C18：2，溶血磷脂酰胆碱酰基C17：0，溶血磷脂酰胆碱酰基C18：0，溶血磷脂酰胆碱酰基C18：1，磷脂酰胆碱酰基 - 烷基C34：2，磷脂酰胆碱酰基 - 烷基C36：2，磷脂酰胆碱酰基 - 烷基C36：3和具有与甘氨酸相同分子量的等压代谢物，溶血磷脂酰胆碱酰基C18：2，溶血磷脂酰胆碱酰基C17：0，溶血磷脂酰胆碱酰基C18：0，溶血磷脂酰胆碱酰基C18：1，磷脂酰胆碱酰基 - 烷基C34：2，磷脂酰胆碱酰基 - 烷基C36：2或磷脂酰胆碱酰基 - 烷基C36：3但化学式不同; 和/或（b）包含代谢物乙酰肉碱C2和具有与乙酰肉碱C2相同的分子量但不同化学式的等压代谢物的第二组; 其中与对照的相应代谢物的量相比，选自所述第一组的代谢物的量的减少或选自所述第二组的代谢物的量的增加表明发生倾向 2型糖尿病 此外，本发明涉及鉴定能够预防2型糖尿病和与其相关的疾病或作为用于开发能够预防2型糖尿病和相关疾病的化合物的铅化合物的化合物的方法，以及选择 治疗预防2型糖尿病。 此外，本发明涉及一种试剂盒。